Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jul 20, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The ENDEAVOR trial is a research study focused on understanding the condition known as infective endocarditis, which is an infection of the inner lining of the heart. Researchers aim to learn more about how this disease progresses and what factors can influence patient outcomes. By analyzing various biological markers in patients, they hope to discover new insights that could improve diagnosis and treatment options for those affected by this condition.
To participate in this study, candidates must have a confirmed diagnosis of infective endocarditis. Unfortunately, those who cannot provide consent or who have serious other health issues that prevent them from providing biological samples will not be eligible. Participants can expect to contribute to important research that might help shape future care for patients with infective endocarditis. The study is currently recruiting individuals and welcomes patients of all genders aged 65 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with clinically confirmed infective endocarditis
- Exclusion Criteria:
- • Patients refuse to sign informed consent form
- • Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
About First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Xi'an Jiaotong University is a leading medical institution renowned for its commitment to advancing healthcare through clinical research and innovative treatment approaches. As a prominent academic hospital in China, it integrates clinical practice, education, and research, fostering a collaborative environment that enables the development of cutting-edge therapies and medical technologies. With a multidisciplinary team of experts and state-of-the-art facilities, the hospital plays a pivotal role in conducting high-quality clinical trials that aim to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
Yang Yan
Principal Investigator
First Affiliated Hospital Xi'an Jiaotong University
Guoliang Li
Principal Investigator
First Affiliated Hospital Xi'an Jiaotong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported